Hervør drives strategic, scientific, and commercial strategies for life science start-ups for them to progress and reach important value inflection points and identify potential critical risks or roadblocks. At BII she is instrumental in scouting, performing due diligence, and anchoring companies in our Venture programs.

She holds an MSc in Biochemistry and a Ph.D. in Biomedical Science from the University of Copenhagen and a Post Doc in Lausanne in Switzerland. Hervør has experience with big Pharma (Novo Nordisk A/S), small BioTech, and Life Science start-up companies and sits on several boards as an observer or full member. She provides scientific guidance for projects and early-stage companies on drug development plans, team competencies, strategic partnerships, and Board.